ClinicalTrials.gg
CompletedNCT00478660RHAPSODYUpdated Oct 10, 2007

An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)

A Phase 3 interventional study of adalimumab (Humira) in Ankylosing Spondylitis, sponsored by Abbott. Completed at 205 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-10-10.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing adalimumab in Spondylitis, Ankylosing — 2 open to participants now, 3 under way, none of them phase 3. Adalimumab · Spondylitis, Ankylosing.

Enrollment
Largest of 19
1,250 · median 80
Started
2006
the only one that year
Phase 3
7 of 19
none open now
Registered
4th of 19
by date
Lead sponsor
5 of 19
Abbott

Among the 19 studies testing adalimumab in Spondylitis, Ankylosing, this one has the largest enrollment, is the only one that started in 2006, is one of 7 in phase 3, and was the 4th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 98 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

2 of the 19 studies testing adalimumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing adalimumab in Spondylitis, Ankylosing, or all of them as a file.
02

Study summary

Due to the rigor of the clinical development program of adalimumab for the indication of AS, the population of subjects with active AS that could enroll in previous phase 3 studies was limited. Therefore, it is necessary to further evaluate the use of adalimumab in a setting that mimics day-to-day clinical practice to obtain further safety and efficacy data by allowing subjects meeting the characteristics noted below to enter this study:

  • Subjects who failed another TNF inhibitor (etanercept, infliximab)
  • Subjects with advanced spinal ankylosis
  • Subjects with AS associated disorders (i.e., uveitis, IBD, and psoriasis)
03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to give written and to comply with the requirements of the study protocol
  • Males and females 18 years of age or older
  • Diagnosis of AS according to the modified New York Criteria for Ankylosing Spondylitis 1984.24
  • Documented active AS based on the opinion of a physician for at least 3 months
  • Active AS with BASDAI >= 4 at the Screening Visit
  • Unsatisfactory response to standard AS therapies in accordance with the current national guidelines for treatment of AS with TNF inhibitors (if applicable) including a minimum of failing at least one NSAID. National guidelines (if applicable) must be followed if the guidelines are more strict regarding the use of TNF inhibitors for the treatment of AS
  • Use of reliable method of , e.g., IUDs, condoms, or hormone (oral, implantable, or injectable) contraceptives by all female subjects of . Subject must follow the manufacture's recommendations of contraception prior to the administration of study drug and through 150 days following the last administration of adalimumab
  • Able and willing to self-administer sc injections or have available a suitable person to administer sc injections
  • A negative pregnancy test (serum HCG) for women of childbearing potential prior to start of study treatment
  • Subject must be evaluated for active and latent TB infection by using a PPD skin test, T SPOT-TB test, chest x-ray and a detailed review of the subject's medical history. Guidelines regarding the treatment of latent TB must be followed prior to the administration of adalimumab

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any agent within 30 days, or five half-lives of the product, which ever is longer
  • Treatment within the last six weeks with infliximab or within the last three weeks with etanercept or previous treatment at any time with adalimumab
  • Known allergy to of adalimumab formulation
  • History of or current acute inflammatory joint disease of origin other than AS, e.g., rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus etc
  • Treatment with (prednisolone equivalents) under the following conditions:

    • Dose is >10 mg/d systemically within the 28 days before screening
    • Intraarticular injections or infiltrations of peripheral joints and tendons within 28 days before or at screening
    • Intraarticular injections of sacroiliac joints without therapeutic response \<=14 days before screening
  • Other medical conditions: uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure ( III-IV), recent stroke (within three months), chronic leg ulcer and any other condition (e.g., indwelling urinary catheter) which, in the opinion of the investigator, would put the subject at risk by participation in the study
  • History of cancer or malignant lymphoproliferative disease other than a successfully treated non- cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix
  • History of positive serology for indicating active infection or history of positive serology for
  • History of positive status
  • Persistent or recurrent infections or severe infections requiring hospitalization or treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment
  • Previous diagnosis or signs highly indicative of central nervous system demyelinating diseases (e.g., optic neuritis, ataxia, apraxia)
  • History of active tuberculosis, histoplasmosis or listeriosis
  • Female subjects who are pregnant or breast-feeding
  • History of drug or alcohol abuse in the last year
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
1,250 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. ASAS 20/40/50/70

  2. ASAS 5/6

  3. BASDAI score

Secondary outcomes

  1. Adverse events

  2. Laboratory data

  3. Vital signs

07

Study locations

205 sites
  • Graz, A-8020, Austria
  • Graz, A-8036, Austria
  • Innsbruck, A-6020, Austria
  • Wien, A-1090, Austria
  • Wien, A-1100, Austria
  • Aalst, 9300, Belgium
  • Belsele, B-9111, Belgium
  • Brugge, 8000, Belgium
  • Charleroi, 6000, Belgium
  • Erembodegem, 9320, Belgium
  • Genk, 3600, Belgium
  • Gent, B-9000, Belgium
  • Hasselt, B-3500, Belgium
  • Oostende, 8400, Belgium
  • Frederiksberg, DK-2000, Denmark
  • Holstebro, DK-7500, Denmark
  • Kolding, DK-6000, Denmark
  • Randers, DK-8900, Denmark
  • Silkeborg, DK-8600, Denmark
  • Helsinki, 00280, Finland
  • Hyvinkaa, 05800, Finland
  • Kouvola, 45100, Finland
  • Turku, 20521, Finland
  • Aix En Provence, 13616, France
  • Aix Les Bains, 73106, France
  • Amiens Cedex, 80054, France
  • Angers Cedex 1, 49033, France
  • Belfort, 90016, France
  • Berck Cedex, 62608, France
  • Besancon, 25030, France
  • Bordeaux Cedex, 33076, France
  • Boulogne Billancourt, 92100, France
  • Brest Cedex, 29609, France
  • Caen-Cedex, 14033, France
  • Cahors, 46005, France
  • Clermont-ferrand, 63003, France
  • Corbeil Essonnes, 91108, France
  • Creteil, 94010, France
  • Dijon Cedex, 21033, France
  • Grenoble, 38043, France
  • Le Kremlin Bicetre, 94275, France
  • Le Mans, 72037, France
  • Levin Cedex, 62806, France
  • Libourne, 33505, France
  • Lille Cedex, 59037, France
  • Limoges, 87042, France
  • Lomme, 59462, France
  • Lyon Cedex 03, 69437, France
  • Lyon Cedex 07, 69365, France
  • Lyon, 69310, France
  • Marseille Cedex 5, 13385, France
  • Marseille Cedex, 13285, France
  • Montivilliers, 76290, France
  • Montpellier Cedex 5, 34295, France
  • Mulhouse Cedex, 68070, France
  • NANTES Cedex, 44035, France
  • Nice, 06202, France
  • Orleans Cedex 01, 45032, France
  • Paris Cedex 10, 75475, France
  • Paris Cedex 13, 75651, France
  • Paris, 75012, France
  • Paris, 75014, France
  • Pau Cedex, 64046, France
  • Poitiers, 86021, France
  • Reims, 51092, France
  • Rennes Cedex, 35203, France
  • Saint Brieuc Cedex 1, 22023, France
  • Saint Etienne, 42055, France
  • Strasbourg, 67098, France
  • Toulouse Cedex 9, 31059, France
  • Tours Cedex, 37044, France
  • Valenciennes, 59322, France
  • Vandoeuvre les Nancy, 54511, France
  • Bad Bentheim, D-48455, Germany
  • Bad Bramstedt, 24576, Germany
  • Bad Nauheim, D-61231, Germany
  • Bad, 83043, Germany
  • Berlin, 10117, Germany
  • Berlin, 12200, Germany
  • Berlin, 13055, Germany
  • Berlin, 13125, Germany
  • Berlin, D-14109, Germany
  • Chemnitz, D-09130, Germany
  • Cottbus, 03048, Germany
  • Damp, 24349, Germany
  • Dresden, 01307, Germany
  • Dresden, D-01067, Germany
  • Duisburg, 47055, Germany
  • Düsseldorf, 40225, Germany
  • Erfurt, 99096, Germany
  • Erlangen, 91054, Germany
  • Frankfurt, 60528, Germany
  • Freiburg, 79106, Germany
  • Goslar, 38640, Germany
  • Göttingen, 37075, Germany
  • Hamburg, 21075, Germany
  • Hamburg, 22147, Germany
  • Hamburg, D-22081, Germany
  • Hannover, 30625, Germany
  • Heidelberg, D-69115, Germany

Showing the first 100 of 205 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12(3):R117. doi: 10.1186/ar3054. Epub 2010 Jun 16. PubMed 20553600 ↗
  • Rudwaleit M, Claudepierre P, Kron M, Kary S, Wong R, Kupper H. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res Ther. 2010;12(2):R43. doi: 10.1186/ar2953. Epub 2010 Mar 15. PubMed 20230622 ↗
  • Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-De-Prati R, Kupper H, Kary S. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009 Apr;36(4):801-8. doi: 10.3899/jrheum.081048. Epub 2009 Feb 27. PubMed 19273449 ↗
  • Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009 May;68(5):696-701. doi: 10.1136/ard.2008.092585. Epub 2008 Jul 28. PubMed 18662932 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 10, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00478660
Lead sponsor
Abbott
First posted
May 25, 2007
Start date
Feb 2006
Last update
Oct 10, 2007

Study contacts

Beverly Paperiello
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion